Home/Filings/4/0001055726-25-000005
4//SEC Filing

Humeau Laurent 4

Accession 0001055726-25-000005

CIK 0001055726other

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 6:06 PM ET

Size

19.4 KB

Accession

0001055726-25-000005

Insider Transaction Report

Form 4
Period: 2025-02-26
Humeau Laurent
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-26+3,85528,192 total
  • Tax Payment

    Common Stock

    2025-02-26$1.98/sh1,584$3,13626,608 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-263,8550 total
    Common Stock (3,855 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-265,01010,019 total
    Common Stock (5,010 underlying)
  • Exercise/Conversion

    Common Stock

    2025-02-26+5,01031,618 total
  • Tax Payment

    Common Stock

    2025-02-26$1.98/sh2,059$4,07729,559 total
  • Award

    Common Stock Option

    2025-02-27+27,40227,402 total
    Exercise: $1.94From: 2025-02-27Exp: 2035-02-27Common Stock (27,402 underlying)
  • Award

    Restricted Stock Unit

    2025-02-27+22,09822,098 total
    Common Stock (22,098 underlying)
Footnotes (6)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,566 restricted stock units granted on February 26, 2022 was as follows: 3,855 shares vested on February 26, 2023; 3,856 shares vested on February 26, 2024; and 3,855 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
  • [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
  • [F3]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 is as follows: 5,010 shares vested on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
  • [F4]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (3) herein.
  • [F5]The vesting schedule for the 27,402 options is as follows: 13,701 shares vested on February 27, 2025 and 13,701 shares will vest on February 26, 2026.
  • [F6]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 22,098 restricted stock units granted on February 27, 2025 is as follows: 7,366 shares will vest on February 26, 2026; 7,366 shares will vest on February 26, 2027; and 7,366 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Issuer

INOVIO PHARMACEUTICALS, INC.

CIK 0001055726

Entity typeother

Related Parties

1
  • filerCIK 0001770390

Filing Metadata

Form type
4
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 6:06 PM ET
Size
19.4 KB